AFFIRM clinical trial

May 4, 2016May 19, 2016

Tonix Pharmaceuticals Completes Enrollment in Fibromyalgia Phase 3 Clinical Trial

News

Tonix Pharmaceuticals, a company developing next-gen therapies for disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD), has completed enrollment in its Phase 3 AFFIRM clinical trial of TNX-102 ... Read more

March 30, 2016May 19, 2016

Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference

News

Tonix Pharmaceuticals, a company dedicated to developing next-gen medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced its Executive Vice President of Commercial Planning and Development, Ronald Notvest, Ph.D., MBA, will present at the ... Read more

March 14, 2016May 19, 2016

Encouraging Potential Treatment Data for Fibromyalgia, PTSD Presented by Tonix Pharmaceuticals

News

Tonix Pharmaceuticals has presented data for TNX-102 SL (cyclobenzaprine HCI sublingual tablets, 2.8 mg), its investigational new drug, at the American Society for Clinical Pharmacology and Therapeutics 2016 Annual Meeting, held March ... Read more